

# Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) - Pipeline Review, H1 2018

<https://marketpublishers.com/r/M4ABC99F099EN.html>

Date: June 2018

Pages: 43

Price: US\$ 3,500.00 (Single User License)

ID: M4ABC99F099EN

## Abstracts

Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) - Pipeline Review, H1 2018

### SUMMARY

Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) - Metabotropic glutamate receptor 7 is a protein encoded by the GRM7 gene. G-protein coupled receptor for glutamate. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase.

Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) pipeline Target constitutes close to 8 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase I, Preclinical and Discovery stages are 1, 1, 2 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Central Nervous System and Ear Nose Throat Disorders which include indications Post-Traumatic Stress Disorder (PTSD), Anxiety Disorders, Acute Sensorineural Hearing Loss, Attention Deficit Hyperactivity Disorder (ADHD), Generalized Anxiety Disorder (GAD), Hearing Disorders, Infantile Spasm (West Syndrome), Opium (Opioid) Addiction, Pervasive Developmental Disorder (PDD), Presbycusis, Rett Syndrome, Status Epilepticus, Tinnitus and Visceral Pain.

The latest report Metabotropic Glutamate Receptor 7 - Pipeline Review, H1 2018, outlays comprehensive information on the Metabotropic Glutamate Receptor 7

(GPRC1G or MGLUR7 or GRM7) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7)

The report reviews Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) targeted therapeutics and enlists all their major and minor projects

The report assesses Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) targeted therapeutics

## **REASONS TO BUY**

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) - Overview

Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) - Therapeutics  
Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) - Therapeutics  
Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) - Companies  
Involved in Therapeutics Development

Addex Therapeutics Ltd

Aevi Genomic Medicine Inc

Pragma Therapeutics SAS

Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) - Drug Profiles  
ADX-71743 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fasoracetam - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JBPOS-0101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LSP-29166 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

## PGT-117 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

## Small Molecule to Agonize mGlu7 for Rett Syndrome - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

## Small Molecules to Antagonize mGluR7 for Acute Sensorineural Hearing Loss, Presbycusis, and Tinnitus - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

## Small Molecules to Antagonize mGluR7 for Central Nervous System Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

## Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) - Dormant Products

## Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) - Product Development Milestones

## Featured News & Press Releases

May 10, 2017: Aevi Genomic Medicine Announces Plans to Initiate Phase 2 Clinical Trial to Confirm Genetic Responders to AEVI-001

Apr 20, 2017: Aevi Genomic Medicine Presents Updated Results from SAGA Trial of AEVI-001 at the 6th World Congress on ADHD

Apr 12, 2017: Aevi Genomic Medicine to Present Updated Results from SAGA Trial of AEVI-001 at the 6th World Congress on ADHD

Mar 20, 2017: Aevi Genomic Medicine Provides Top-line Results from the SAGA Trial of AEVI-001

Jan 31, 2017: Aevi Genomic Medicine Announces Enrollment of First Patient in Phase 1/2 Clinical Trial of AEVI-001 in 22q Deletion Syndrome

Jan 04, 2017: Aevi Genomic Medicine Announces Completion of Enrollment for Phase 2/3 SAGA Clinical Trial of AEVI-001 (NFC-1) in mGluR+ ADHD Adolescents

Oct 29, 2016: Medgenics Presents New Data Showing Prevalence of Genetic Mutations in Pediatric Populations with Attention Deficit Hyperactivity Disorder

Sep 01, 2016: PRAGMA Therapeutics and UK Ministry of Defences Center for Defence Enterprise collaborate to support preclinical research on innovative treatment for tinnitus

Jun 17, 2016: Medgenics Announces Enrollment of First Patient in Phase 2/3 Clinical Trial of NFC-1 in Adolescents With mGluR Mutation Positive ADHD

Jun 13, 2016: Addex mGluR7 Program Demonstrate Potential in Preclinical Models of Neurodegenerative and Psychiatric Diseases

Apr 25, 2016: PRAGMA Therapeutics awarded first prize and ?300,000 from UK charity Action on Hearing Loss to develop new drugs to treat Hearing Loss

Nov 23, 2015: Addex and CHUV-UNIL Collaborators Awarded Swiss Grant to Advance Addex mGluR7 Allosteric Modulator for Neurodegenerative and Psychiatric Diseases

Nov 23, 2015: The SEVEN4PTSD consortium led by PRAGMA Therapeutics awarded 2015 French ANR grant to further advance its mGlu7 program for Post-Traumatic Stress Disorder

Dec 20, 2012: Addex Scientists Discover and Characterize First Potent and Selective Small Molecule Negative Allosteric Modulator Targeting mGlu7 Receptor

Oct 02, 2012: Addex Therapeutics And Collaborators Receive CHF700,000 Grant To Develop Allosteric Modulators For Neurodegenerative And Psychiatric Diseases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2018  
Number of Products under Development by Therapy Areas, H1 2018  
Number of Products under Development by Indication, H1 2018  
Number of Products under Development by Companies, H1 2018  
Products under Development by Companies, H1 2018  
Number of Products under Investigation by Universities/Institutes, H1 2018  
Products under Investigation by Universities/Institutes, H1 2018  
Number of Products by Stage and Mechanism of Actions, H1 2018  
Number of Products by Stage and Route of Administration, H1 2018  
Number of Products by Stage and Molecule Type, H1 2018  
Pipeline by Addex Therapeutics Ltd, H1 2018  
Pipeline by Aevi Genomic Medicine Inc, H1 2018  
Pipeline by Pragma Therapeutics SAS, H1 2018  
Dormant Projects, H1 2018

## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

### COMPANIES MENTIONED

Addex Therapeutics Ltd

Aevi Genomic Medicine Inc

Pragma Therapeutics SAS



## I would like to order

Product name: Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) - Pipeline Review, H1 2018

Product link: <https://marketpublishers.com/r/M4ABC99F099EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/M4ABC99F099EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

